FDA Issues EUA for Third COVID-19 Vaccine

On February 27, 2021, the US Food and Drug Administration issued an emergency use authorization (EUA) for the Janssen COVID-19 vaccine. This is the third vaccine authorized by the FDA to prevent COVID-19.

This follows shortly after positive results were released last week detailing the vaccine’s effectiveness against moderate to severe disease and an FDA evaluation that determined that the vaccine’s known and potential benefits outweigh its known and potential risks in individuals aged 18 years and older.

The vaccine uses an adenovirus type 26 to deliver the DN from the spike protein of the SARS-CoV-2 virus.

The most commonly reported adverse effects were injection site pain, headache, fatigue, muscle aches, and nausea, most of which lasted 1 to 2 days.

—Michael Potts

Reference:

FDA issues emergency use authorization for third covid-19 vaccine. News release. US Food and Drug Administration. Published February 27, 2021. Accessed March 1, 2021. https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine